Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

NCT02453594 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

211

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

BIOLOGICAL: pembrolizumab

Sponsor

Merck Sharp & Dohme LLC